PAPILLON trial

Rybrevant Redefines First-Line Care for Patients with EGFR Exon 20 Insertion Mutation (ESMO 2023)

ESMO 2023: LBA5 Targeted therapies have revolutionized the treatment of EGFR-mutant NSCLC in the last 20 years. However, EGFR exon ...